These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16522992)

  • 1. Controlled-release doxazosin as combination therapy in hypertension: the GATES study.
    Black HR; Keck M; Meredith P; Bullen K; Quinn S; Koren A
    J Clin Hypertens (Greenwich); 2006 Mar; 8(3):159-66; quiz 167-8. PubMed ID: 16522992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension.
    Calvo C; Gil-Extremera B; Gomez-Fernández P; Masramon X; Pueyo C; Armada B
    Int J Cardiol; 2005 May; 101(1):97-104. PubMed ID: 15860390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group.
    Os I; Stokke HP
    J Cardiovasc Pharmacol; 1999 May; 33(5):791-7. PubMed ID: 10226868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study.
    de Alvaro F; Hernández-Presa MA;
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):271-6. PubMed ID: 16495766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.
    Black HR; Sollins JS; Garofalo JL
    Am J Hypertens; 2000 May; 13(5 Pt 1):468-74. PubMed ID: 10826396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension.
    Os I; Stokke HP
    Blood Press; 1999; 8(3):184-91. PubMed ID: 10595697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension.
    Anegón M; Esteban J; Jiménez-García R; Sanz de Burgoa V; Martínez J; Gil de Miguel A
    Clin Ther; 2002 May; 24(5):786-97. PubMed ID: 12075946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure.
    Os I
    Int J Clin Pharmacol Ther; 2006 Mar; 44(3):99-106. PubMed ID: 16550731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia.
    Goldsmith DR; Plosker GL
    Drugs; 2005; 65(14):2037-47. PubMed ID: 16162024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxazosin gastrointestinal therapeutic system: a clinical perspective.
    Mann SJ
    J Clin Hypertens (Greenwich); 2006 Mar; 8(3):207-8. PubMed ID: 16522999
    [No Abstract]   [Full Text] [Related]  

  • 13. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; Domínguez MJ; Covelo M; Fernández JR; Fontao MJ; López JE
    Chronobiol Int; 2004 Mar; 21(2):277-96. PubMed ID: 15332347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg.
    Oliveras A; Hurtado S; Vázquez S; Puig JM; Lloveras J
    Transplant Proc; 2003 Aug; 35(5):1732-5. PubMed ID: 12962775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies.
    Lund-Johansen P; Kirby RS
    Blood Press Suppl; 2003 May; 1():5-13. PubMed ID: 12800982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).
    Guthrie RM; Siegel RL
    Clin Ther; 1999 Oct; 21(10):1732-48. PubMed ID: 10566569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide.
    Grimm RH; Flack JM; Schoenberger JA; Gonzalez NM; Liebson PR
    Am J Hypertens; 1996 May; 9(5):445-54. PubMed ID: 8735175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
    Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K
    BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
    Englert RG; Mauersberger H
    Am Heart J; 1988 Dec; 116(6 Pt 2):1826-32. PubMed ID: 2904758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.